INmune Bio (INMB) Competitors $2.41 +0.06 (+2.55%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.36 -0.05 (-2.03%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. ANNX, NMRA, VOR, ALMS, IMMP, TKNO, SCPH, ALLO, SGMT, and SOPHShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Annexon (ANNX), Neumora Therapeutics (NMRA), Vor Biopharma (VOR), Alumis (ALMS), Prima BioMed (IMMP), Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Its Competitors Annexon Neumora Therapeutics Vor Biopharma Alumis Prima BioMed Alpha Teknova scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Annexon (NASDAQ:ANNX) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends. Which has better earnings and valuation, ANNX or INMB? INmune Bio has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$138.20M-$1.29-1.79INmune Bio$50K1,281.40-$42.08M-$2.48-0.97 Do insiders and institutionals have more ownership in ANNX or INMB? 12.7% of INmune Bio shares are owned by institutional investors. 11.9% of Annexon shares are owned by insiders. Comparatively, 35.7% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ANNX or INMB more profitable? Annexon's return on equity of -70.04% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -70.04% -57.67% INmune Bio N/A -120.62%-92.94% Which has more risk & volatility, ANNX or INMB? Annexon has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Do analysts recommend ANNX or INMB? Annexon currently has a consensus price target of $12.50, indicating a potential upside of 441.13%. INmune Bio has a consensus price target of $18.40, indicating a potential upside of 663.49%. Given INmune Bio's higher probable upside, analysts plainly believe INmune Bio is more favorable than Annexon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75INmune Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Does the media prefer ANNX or INMB? In the previous week, Annexon had 3 more articles in the media than INmune Bio. MarketBeat recorded 5 mentions for Annexon and 2 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.67 beat Annexon's score of 0.54 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryINmune Bio beats Annexon on 8 of the 14 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.48M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-0.9721.1431.2526.05Price / Sales1,281.40345.39433.91193.97Price / CashN/A43.1937.7358.48Price / Book2.218.129.536.61Net Income-$42.08M-$54.72M$3.26B$265.65M7 Day Performance-4.74%2.62%2.13%2.03%1 Month Performance-15.73%2.68%2.80%-0.31%1 Year Performance-65.32%10.93%30.68%19.06% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio1.9945 of 5 stars$2.41+2.6%$18.40+663.5%-62.6%$62.48M$50K-0.9710ANNXAnnexon2.7347 of 5 stars$2.35-3.7%$12.50+431.9%-60.2%$267.70MN/A0.0060NMRANeumora Therapeutics2.3628 of 5 stars$1.64+0.6%$7.14+335.5%-85.9%$263.97MN/A0.00108VORVor Biopharma1.9451 of 5 stars$2.04-4.7%$6.07+197.4%+135.9%$258.43MN/A-1.24140ALMSAlumis2.4386 of 5 stars$4.85+2.1%$20.17+315.8%-62.5%$258.43MN/A0.00N/AIMMPPrima BioMed0.9963 of 5 stars$1.78+2.9%$7.00+293.3%-26.3%$253.94M$5.14M0.002,021Positive NewsUpcoming EarningsGap UpTKNOAlpha Teknova1.6918 of 5 stars$4.41-6.0%$10.00+126.8%-3.5%$250.99M$37.74M-10.50240SCPHscPharmaceuticals4.5444 of 5 stars$4.78+3.9%$14.00+192.9%-5.6%$245.17M$36.33M-2.6430Short Interest ↓ALLOAllogene Therapeutics2.8357 of 5 stars$1.09-0.9%$8.44+674.7%-54.1%$244.07M$20K-0.98310SGMTSagimet Biosciences3.2234 of 5 stars$7.55-1.6%$25.67+240.0%+144.3%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.9553 of 5 stars$3.49+0.6%$8.00+129.2%+2.0%$234.50M$65.17M-7.93520Positive NewsGap Up Related Companies and Tools Related Companies Annexon Competitors Neumora Therapeutics Competitors Vor Biopharma Competitors Alumis Competitors Prima BioMed Competitors Alpha Teknova Competitors scPharmaceuticals Competitors Allogene Therapeutics Competitors Sagimet Biosciences Competitors SOPHiA GENETICS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access